Loading
Give every tumour board a tool that pulls up the relevant trials and guideline lines for each case with citations, records what was decided, and later shows how the patient did.
Molecular tumour boards spend much of their time on literature search and produce recommendations that are rarely tracked to outcomes. The proposal is an assistant built on the evidence graph and computable guidelines: it prepares a cited evidence brief per case, records the board's recommendation in structured form, and links it to the patient's subsequent treatment and outcome, creating a learning loop across boards. Precedents include MSK's OncoKB-driven annotation and academic MTB decision-support pilots.
Shares The answer is 17 years, what is the question: understanding time lags in translational research, Weak real-world evidence and registries, Knowledge reaches practice too slowly.
Shares Decision support that cites the exact trial and guideline line it relies on, OncoKB, Knowledge reaches practice too slowly.
Shares The answer is 17 years, what is the question: understanding time lags in translational research, Knowledge reaches practice too slowly.
Shares The answer is 17 years, what is the question: understanding time lags in translational research, Knowledge reaches practice too slowly.
Shares The answer is 17 years, what is the question: understanding time lags in translational research, Knowledge reaches practice too slowly.
Shares The answer is 17 years, what is the question: understanding time lags in translational research, Knowledge reaches practice too slowly.
Shares The answer is 17 years, what is the question: understanding time lags in translational research, Knowledge reaches practice too slowly.
Shares The answer is 17 years, what is the question: understanding time lags in translational research, Knowledge reaches practice too slowly.